{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:01:39Z","timestamp":1784894499031,"version":"3.55.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,7,22]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction\/Objective:<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) accounts for\nover 85% of lung cancers, and current immunotherapies benefit only a subset of patients. Necroptosis, a regulated form of necrotic cell death, has emerged as a potential\ntherapeutic axis in tumours resistant to apoptosis. This study aimed to develop and validate a necroptosis-related long noncoding RNA (lncRNA) prognostic signature for NSCLC and to explore its associations with tumour immune contexture and predicted drug\nsensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>RNA-seq and clinical data from TCGA and GTEx (1,128 tumours; 110 normal lung samples; 1,027 patients after filtering) were analysed. Necroptosis-related lncRNAs were identified by co-expression analysis with 67 necroptosis genes (Pearson r &gt;\n0.4, P &lt; .001). Candidate lncRNAs associated with overall survival were selected by univariable Cox regression, refined through LASSO-penalised Cox regression with 10-fold\ncross-validation repeated 1,000 times, and further filtered by multivariable Cox analysis\nto construct the final risk model. Model performance was evaluated using time-dependent ROC curves and a clinical nomogram. QRT-PCR validated differential expression\nin A549 and NCI-H1299 versus BEAS-2B cell lines. Immune profiling was performed\nusing seven deconvolution algorithms and single-sample GSEA (ssGSEA). Consensus\nclustering was applied to classify tumour immune phenotypes, and drug sensitivity was\nestimated using the pRRophetic algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A 12-lncRNA signature stratified overall survival across training, test, and\nwhole cohorts and remained independent of tumour stage in multivariable analysis.\nTime-dependent ROC curves yielded AUCs of 0.684, 0.652, and 0.624 at 1, 3, and 5\nyears, respectively. A nomogram integrating the risk score with clinicopathological variables demonstrated strong calibration. qRT-PCR confirmed differential expression of\nthe model lncRNAs between NSCLC and normal bronchial epithelial cell lines. GSEA\nrevealed enrichment of metabolic programmes in low-risk tumours and adhesion\/cytoskeletal pathways in high-risk tumours. Immune deconvolution indicated a mixed immune milieu in high-risk tumours, with increased infiltration estimates concurrent with\nelevated expression of inhibitory checkpoints. Consensus clustering defined two groups:\nan inflamed \u201chot-like\u201d cluster with higher immune\/stromal scores and lower predicted\nIC50 values for multiple targeted and cytotoxic agents, and a comparatively \u201ccold-like\u201d\ncluster.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The 12-lncRNA risk model captures biologically distinct tumour states characterised by divergent pathway activation, distinct immune microenvironmental composition, and predicted drug-sensitivity profiles. The co-occurrence of immune infiltration\nand inhibitory checkpoint enrichment in high-risk tumours suggests immune dysfunction rather than effective antitumour immunity, with direct implications for immunotherapy stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This necroptosis-related lncRNA signature provides a framework for prognostic prediction, tumour immune phenotyping, and therapeutic prioritisation in NSCLC. Prospective external validation and mechanistic functional studies are warranted\nto confirm clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673494471260630122005","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:42Z","timestamp":1784891442000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment and Validation of a Necroptosis-Related Long\nNoncoding RNA Prognostic Model for Non-Small Cell Lung Cancer"],"prefix":"10.2174","volume":"33","author":[{"given":"Zuojuan","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First MedicalUniversity, Jinan, 250000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First MedicalUniversity, Jinan, 250000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First MedicalUniversity, Jinan, 250000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673494471260630122005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/256465\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673494471260630122005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:10:56Z","timestamp":1784891456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/256465\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673494471260630122005","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2026-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}